London, UK, 23 September 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi. Vicebio is developing next-generation vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The …

Read More